
Why Ozempic and Wegovy Might Change Some People's Favorite Foods
Similar to Fraser, other users of Wegovy (known in its generic form as semaglutide), along with those of Ozempic (a form of semaglutide used to treat type 2 diabetes), Zepbound (known generically as tirzepatide) and other medications broadly called glucagonlike peptide 1 (GLP-1) receptor agonists, have described peculiar changes in the way food tastes. GLP-1 drugs—initially designed to help treat type 2 diabetes by triggering insulin release—can cause weight loss by making people feel full faster. But some people report that in addition to an increase in satiety, they experience changes in their preferences for specific foods—they find meats suddenly repulsive, fried foods too heavy and savory snacks unappealing. On online forums and in scientific surveys, some people have expressed a general loss of interest in food overall—a few have even said that the drugs have redefined food as a necessity rather than a joy for them. These accounts may even be captured in grocery store data that suggest people on GLP-1 medications spend less on food, especially calorie-dense and processed items.
Some preliminary evidence suggests changes in food preferences might play a role in weight loss, but it's not clear how much such changes contribute to that result compared with the medications' effect on satiety. And research on the phenomenon has mostly involved animal models or small studies of humans. Experts, however, are starting to gain some clues as to how common these apparent shifts in food preference and taste really are among users and what might be behind them.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
A recent study published in Food Quality and Preference found that people on GLP-1 medications reported reaching for processed foods, as well as refined grains and beef, less often. They also said they were drinking less soda and other sweetened drinks and increasing their intake of fruit, leafy greens and water. Further, they reported consuming about 700 fewer calories per day. These findings rely on self-reported data, however, which can sometimes be unreliable, says Brandon McFadden, a professor in food policy economics at the University of Arkansas and co-author of the study.
Additionally, although GLP-1 users reported eating fewer calorie-dense foods, most people didn't necessarily lose all desire for them. This is because liking a food is different from wanting it, says John Blundell, an emeritus professor in psychobiology at the University of Leeds in England, who was not involved in the recent paper. A person might not find a food particularly tasty (in other words, they might not enjoy the specific sensory experience of consuming it) but still have a strong behavioral drive to eat it. GLP-1 medications seem to involve the reverse: people still like certain foods but have less of an immediate urge to eat them.
These drugs mimic a hormone called GLP-1, which the gut naturally secretes in response to food and which binds to the hormone's receptors around the body—including in brain areas involved in appetite regulation and in reward pathways that reduce the pleasure response to food. Researchers have found that this is the primary way the drugs cause people to lose weight, and some think it might be involved in altered food preferences.
Desires for specific foods can change depending on whether a person is generally hungry or full. For example, when you're hungry, you're more likely to want meaty, high-protein or sometimes high-fat foods rather than sweet ones, Blundell explains. 'When you become full, the reverse happens,' he says: a big piece of meat or a high-fat food becomes aversive—but you might feel like you have a so-called second stomach for dessert. One plausible explanation for this, Blundell says, could be that GLP-1 drugs' satiating effect simply makes such end-of-meal preferences kick in. It's also possible that some aspects of the drugs' compounds could directly act on specific food preferences through some other biological mechanism. 'But it hasn't been demonstrated,' says Blundell, who is working with a food company to develop foods that are more palatable for people on GLP-1 medications.
Blundell led a small study, published in 2017, that found people taking semaglutide not only reduced their overall daily food intake but also preferred and consumed fewer high-fat and savory foods. Previous research that he published in 2007 showed that being full also diminishes similar cravings.
But satiety alone may not fully explain the shift in eating preferences. Emerging evidence and anecdotal user accounts suggest changes to the body's taste mechanisms could also play a role. Some users describe flavors becoming stronger or unpleasant while on the medications, though individual experiences seem to vary: Siobhan, a Los Angeles–based writer, who has been taking Wegovy since 2021 and withheld her last name for privacy, says she still finds fatty foods such as French fries appealing—but her favorite food, panang curry, has become too bitter. 'I've been eating that curry for 20 years,' Siobhan says. 'It just didn't taste right anymore.' Two-year Wegovy user Sarah Streby says she can no longer stomach eggs or broccoli, and her love for spicy food has waned—causing her to change how she cooks for her family. 'Now everyone's complaining the food is too mild because [I] can't handle the spice,' she says.
At press time, Novo Nordisk, the manufacturer of Wegovy and Ozempic, had not responded to a request for comment from Scientific American. A spokesperson for Eli Lilly, which makes the weight-loss drug Zepbound, told Scientific American in an e-mail, 'We do not have data to share concerning changes in food taste or preference among individuals taking GLP-1 medications.' The spokesperson added that known side effects are listed on the medication's labels and that anyone experiencing those side effects should contact their health care provider.
Scientists have found GLP-1 receptors in human taste buds, which hints at a possible explanation for alterations in taste, but findings remain mixed. Some past research has found that people with a higher body weight tend to perceive flavors less intensely, and some evidence suggests this may prompt people to eat more in an attempt to get a bigger sensory reward. In the case of sweet foods, people with a higher body weight also may be less able to perceive a high sugar content, though findings on this have been contradictory. A small study presented at the Endocrine Society's 2024 annual conference found that women taking semaglutide were more sensitive to taste compared with those on a placebo. Brain scans showed increased activity in a region involved in processing sensory rewards when participants tasted something sweet, suggesting that semaglutide may heighten taste perception and make certain foods less appealing.
But another study published in March in Physiology & Behavior seems to suggest the opposite. It found that 46 people taking these medications experienced a reduced sensitivity to all five basic tastes —sweet, sour, salty, bitter and brothy (or umami)—compared with people in a control group. Past studies in mice linked the activation of GLP-1 receptors to alterations in sweet taste perception, but researchers were surprised to see that the effect in humans was broader than anticipated, says Richard Doty, director of the Smell and Taste Center at the University of Pennsylvania and co-author of the March paper. Previous research that linked GLP-1 medications to alterations in taste has mostly looked at diabetic populations, Doty says, adding that 'the focus has always been on sugar, and so people haven't looked at the other sensory systems any great detail.' He suspects the GLP-1 receptors found in taste buds are behind the March findings, 'but we really don't know; there needs to be more research on that.'
For some, the drugs' effects on satiety and taste are welcome changes that make it easier to eat less. But for others, it's more complicated. 'Not only am I not cooking or really taking an interest in food—if I want it, it's sweets,' Fraser says. 'And even then, if it's super sweet, I'll take a bite or two, and I'm like, I gotta put it down.' She says savory foods have lost their appeal entirely.
Fraser is still considering the trade-offs for the improvements she's seen in her health as she navigates this shift and deals with the loss of a loved hobby. But 'the mental load of weight loss has been greatly reduced,' she says, 'and that is worth it to me.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Novo cuts guidance, names new CEO as obesity drug challenges mount
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novo Nordisk on Tuesday substantially cut its financial forecasts for the year as cheap, knockoff versions of its popular obesity drug Wegovy continue to hold back the pharmaceutical company's growth. The Danish drugmaker now expects sales to increase in 2025 by between 8% and 14%, revising down its May prediction of 13% to 21% growth. Operating profit is also expected to be lower by four to eight percentage points than previously estimated. Shares tumbled downward by more than 20% in U.S. trading on the news Tuesday morning, erasing over $60 billion in market capitalization. Alongside the guidance cut, Novo named company veteran Maziar Mike Doustdar as successor to outgoing CEO Lars Fruergaard Jørgensen, who announced plans in May to step down. The company is also reorganizing its research and development, merging two units into a single division that will be led by Martin Holst Lange, who will become Novo's chief scientist on Aug. 7, the same day Doustdar takes over from Jørgensen. Novo remains a leading company in what's become the pharma industry's fastest-growing market. Ozempic and Wegovy, the branded versions of the GLP-1 drug semaglutide that it respectively sells for diabetes and weight loss, are bringing in tens of billions of dollars in sales. But Novo's financial and leadership adjustments reflect the company's realization its position is slipping. Compounded versions of semaglutide, which were allowed to enter the U.S. market when Ozempic and Wegovy were in shortage, continue to cannibalize Novo's sales, even after regulators ruled they could no longer be sold en masse. Novo's solutions haven't worked as well as hoped, either. While the company brought Ozempic and Wegovy back into full supply, its attempt to compete on price with lower-cost compounded drugs isn't bearing fruit. Direct-to-consumer programs that offered the drugs at a cheaper cash price have only yielded about 30,000 prescriptions this year, Novo said Tuesday. A marketing alliance with telehealth provider Hims & Hers, meanwhile, ended in acrimony just eight weeks after it began in April. Novo accused Hims of continuing to sell knockoff Wegovy, while Hims CEO Andrew Dudum attacked Novo for allegedly pushing Hims to steer patients to its obesity product. 'This is an important moment for Novo Nordisk,' board chair Helge Lund said in a statement on Doustdar's appointment. 'The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition.' In addition to its problems with compounders, Novo is losing ground to Eli Lilly, which sells the rival GLP-1 drug Zepbound for obesity. Clinical testing showed Zepbound can deliver greater weight loss than Wegovy, although Novo can claim a cardio-protective benefit for its drug that Lilly can't yet. Lilly has also out-positioned Novo in development of successor drugs to Wegovy and Zepbound, finding success in testing with a pill called orforglipron. Novo cited competition as a factor in downgrading its outlook for Wegovy and Ozempic sales in the U.S. The company hopes that recent changes in insurer CVS' drug formulary will help lift Wegovy moving forward. Rebuilding momentum will be Doustdar's priority. The executive has led Novo's international division, which includes the company's businesses outside of the U.S., since 2013. He previously oversaw commercial activities in Southeast Asia, Oceania and the Middle East. 'I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need,' Doustdar said in a statement. Novo said its search for a replacement to Jørgensen included internal and external candidates. Some analysts had expected the company to choose a leader from outside the company. Recommended Reading Novo abruptly ends obesity drug deal with Hims Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Wegovy maker Novo's profit warning triggers $70 billion share rout
By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." NEW CEO AN INSIDER Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. ($1 = 0.8672 euros) Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
FDA's Makary wants to increase drug access, reduce 'addictive' foods
FDA Commissioner Marty Makary has an ambitious plan to overhaul how quickly patients can access drugs in the US, but also wants to reduce reliance on pharmaceuticals by shifting the focus of research to finding the root causes of common diseases. At the top of his list is reducing Americans' consumption of ultra-processed foods and making subsidized federal food programs healthier. "No one has been talking about the fact that food has been designed to be addictive. So when we have a crisis in our nation's children, that is, 40% have a chronic disease and 31% have prediabetes or insulin resistance, it's not their fault," Makary told Yahoo Finance in an interview Wednesday. "We don't think that our childhood obesity epidemic is a willpower problem. We think this is something adults are doing to kids," Makary added. He spoke with Yahoo Finance while on a nationwide tour to connect with drug industry leaders at companies big and small. But while Makary is focused on streamlining access to medicines and allowing access to some that may not be fully tested in traditional clinical trials, he is also focused on reducing the use of drugs in daily life. "We've got to talk about school lunch programs, not just putting every 6-year-old on Ozempic," Makary said, referencing the blockbuster diabetes drug from Novo Nordisk (NVO). "We've got to talk about sleep medicine and the quality of sleep, not just antihypertensive after antihypertensive [drugs that treat high blood pressure]. And we've gotta talk about environmental exposures that cause cancer, not just the chemo to treat it. We've got to talk about food as medicine and the microbiome," Makary said. He has also been vocal about revamping the food pyramid, which hasn't been updated in more than a decade, and sees it as one path to regaining trust in the agency — which has declined in the years since the pandemic. "We are going to rewrite those dietary guidelines. I think that'll go a long way too in rebuilding trust," Makary said. Research and rebuilding trust In addition to the FDA's work in addressing chronic diseases, the National Institutes of Health (NIH) are also directing funds to do the same. When asked about cuts to health equity-focused research, including women's health, Makary defended the Trump administration's moves to cut some federally funded research, to the tune of $18 billion, or a 40% reduction. "The NIH, when we came into office, was a mess. Fourteen percent of grants went to descriptive studies on health equity, not reducing health equities." Meanwhile, Makary has been focused on ensuring quicker access to drugs, questioning why it takes 10 years for a drug to reach market, and more transparency about drugs that are approved. He did not specify when the public would get greater access to decision letters, but continued to promise more access. "We're releasing the FDA decision letters so the public can see them, drug developers can see them. We can give more predictability. We're modernizing the agency. We're trying to cut some of the idle time," Makary said, noting this was key to rebuilding trust as well. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data